Search

Your search keyword '"Kaye, James A."' showing total 663 results
Start Over Author "Kaye, James A."
663 results on '"Kaye, James A."'

5. BRCA testing and outcomes in women with breast cancer

Author

Stenehjem, David D., Telford, Claire, Unni, Sudhir K., Bauer, Hillevi, Sainski, Amy, Deka, Rishi, Schauerhamer, Marisa B., Ye, Xiangyang, Tak, Casey R., Ma, Junjie, Dalvi, Tapashi B., Gutierrez, Lia, Kaye, James A., Tyczynski, Jerzy E., Brixner, Diana I., and Biskupiak, Joseph E.

Published
2021
Full Text
View/download PDF

11. Validation of an ICD‐10 case‐finding algorithm for endometrial cancer in US insurance claims.

Author

Djibo, Djeneba Audrey, Margulis, Andrea V., McMahill‐Walraven, Cheryl N., Saltus, Catherine W., Shuminski, Patricia, Kaye, James A., Johannes, Catherine B., Libertin, Mark, and Graham, Shelli

Abstract

Purpose: To evaluate the positive predictive value (PPV) of an endometrial cancer case finding algorithm using International Classification of Disease 10th revision Clinical Modification (ICD‐10‐CM) diagnosis codes from US insurance claims for implementation in a planned post‐marketing safety study. Two algorithm variants were evaluated. Methods: Provisional incident endometrial cancer cases were identified from 2016 through 2020 among women aged ≥50 years. One algorithm variant used diagnosis codes for malignant neoplasms of uterine sites (C54.x), excluding C54.2 (malignant neoplasm of myometrium); the other used only C54.1 (malignant neoplasm of endometrium). A random sample of medical records of recent incident provisional cases (2018–2020) was requested for adjudication. Confirmed cases showed biopsy evidence of endometrial cancer, documentation of cancer staging, or hysterectomy following diagnosis. We estimated the PPV of the variants with 95% confidence intervals (CI) excluding cases that had insufficient information. Results: Of 294 provisional cases adjudicated, 85% were from outpatient settings (n = 249). Mean age at diagnosis was 69.3 years. Among the 294 adjudicated cases (identified with the broader algorithm variant), the same 223 were confirmed endometrial cancer cases by both algorithm variants. The PPV (95% CI) for the broader algorithm variant was 84.2% (79.2% and 88.3%), and for the variant using only C54.1 was 85.8% (80.9% and 89.8%). Conclusion: We developed and validated an algorithm using ICD‐10‐CM diagnosis codes to identify endometrial cancer cases in health insurance claims with a sufficiently high PPV to use in a planned post‐marketing safety study. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. New Technology Applied to Distribution of Audio Tutorial Lessons.

Author

Ampex Corp., Sunnyvale, CA. and Kaye, James M.

Abstract

Audiotutorial instruction is one application of instruction tailored to individual needs. This method imposes certain requirements for instruction to be effective and for students to be properly motivated to learn. Some of the key requirements are: (1) individual control of the program material, (2) convenience of materials acquisition by the student, (3) simplicity of presentation methods, (4) costs, (5) timeliness of materials available, and (6) ease of courseware development. The Ampex Pyramid System satisfies each of these requirements. In its simplest form, the system provides high speed cassette copies of any program in its master storage bank. In a second form, the student accesses the system from a terminal located at a carrel. In addition, a feature may be added which allows the same functions described above to be performed at home using a touch tone telephone. Another feature is that of student response and conditional branching. Most importantly, the system has been purposely designed to allow a full range of presentations from very simple linear program presentations to sophisticated, fully interactive, multimedia lessons with conditional branching. All may be presented on the system without a significant investment of time and dollars in computer software. (WCM)

Published
1974

30. Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Author

Arana, Alejandro, primary, Pottegård, Anton, additional, Kuiper, Josephina G, additional, Booth, Helen, additional, Reutfors, Johan, additional, Calingaert, Brian, additional, Lund, Lars Christian, additional, Crellin, Elizabeth, additional, Schmitt-Egenolf, Marcus, additional, Kaye, James A, additional, Gembert, Karin, additional, Rothman, Kenneth J, additional, Kieler, Helle, additional, Dedman, Daniel, additional, Houben, Eline, additional, Gutiérrez, Lia, additional, Hallas, Jesper, additional, and Perez-Gutthann, Susana, additional

Published
2021
Full Text
View/download PDF

36. Measles, Mumps, And Rubella (Mmr) Vaccine And Autism

Author

Smeeth, Liam, Hall, Andrew J., Rodrigues, Laura C., Huang, Xiangning, Smith, Peter G., Fombonne, Eric, Edwardes, Michael, Baltzan, Marc, Yazbak, F. Edward, Kaye, James A., Melero-Montes, Maria del Mar, and Jick, Hershel

Published
2001

41. Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus : Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Author

Arana, Alejandro, Pottegård, Anton, Kuiper, Josephina G., Booth, Helen, Reutfors, Johan, Calingaert, Brian, Lund, Lars Christian, Crellin, Elizabeth, Schmitt-Egenolf, Marcus, Kaye, James A., Gembert, Karin, Rothman, Kenneth J., Kieler, Helle, Dedman, Daniel, Houben, Eline, Gutiérrez, Lia, Hallas, Jesper, Perez-Gutthann, Susana, Arana, Alejandro, Pottegård, Anton, Kuiper, Josephina G., Booth, Helen, Reutfors, Johan, Calingaert, Brian, Lund, Lars Christian, Crellin, Elizabeth, Schmitt-Egenolf, Marcus, Kaye, James A., Gembert, Karin, Rothman, Kenneth J., Kieler, Helle, Dedman, Daniel, Houben, Eline, Gutiérrez, Lia, Hallas, Jesper, and Perez-Gutthann, Susana

Abstract

Purpose: Evidence is insufficient to infer whether topical calcineurin inhibitors (TCIs; tacrolimus and pimecrolimus) cause malignancy. The study objective was to estimate the long-term risk of skin cancer and lymphoma associated with topical TCI use in adults and children, separately. Patients and Methods: A cohort study in Denmark, Sweden, UK, and the Netherlands was conducted. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated for nonmelanoma skin cancer (NMSC), melanoma, cutaneous T-cell lymphoma (CTCL), non-Hodgkin lymphoma (NHL) excluding CTCL, and Hodgkin lymphoma (HL) in new users of TCIs versus users of moderate/high-potency topical corticosteroids. Results: The study included 126,908/61,841 adults and 32,605/27,961 children initiating treatment with tacrolimus/pimecrolimus, respectively. Follow-up was ≥10 years for 19% of adults and 32% of children. Incidence rate ratios and (95% confidence intervals) for tacrolimus versus corticosteroid users in adults were <1 for melanoma, non-Hodgkin lymphoma, and Hodgkin lymphoma; and 1.80 (1.25-2.58) for cutaneous T-cell lymphoma. For pimecrolimus, IRRs in adults were <1 for non-Hodgkin lymphoma, cutaneous T-cell lymphoma, and Hodgkin's lymphoma; and 1.21 (1.03-1.41) for melanoma; and 1.28 (1.20-1.35) for nonmelanoma skin cancer. In children, results were inconclusive due to few events. In adults, incidence rate ratios ≥5 years after first topical calcineurin inhibitor exposure were not higher than in overall analyses. Conclusion: Overall, we found little evidence associating use of topical calcineurin inhibitors with skin cancer and lymphoma; confounding by indication, surveillance bias, and reverse causation may have influenced these results. Even if causal, the public health impact of these excess risks would be low and confined to the first years of exposure.

Published
2021
Full Text
View/download PDF

42. Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)

Author

Arana,Alejandro, Pottegård,Anton, Kuiper,Josephina G, Booth,Helen, Reutfors,Johan, Calingaert,Brian, Lund,Lars Christian, Crellin,Elizabeth, Schmitt-Egenolf,Marcus, Kaye,James A, Gembert,Karin, Rothman,Kenneth J, Kieler,Helle, Dedman,Daniel, Houben,Eline, Gutiérrez,Lia, Hallas,Jesper, Perez-Gutthann,Susana, Arana,Alejandro, Pottegård,Anton, Kuiper,Josephina G, Booth,Helen, Reutfors,Johan, Calingaert,Brian, Lund,Lars Christian, Crellin,Elizabeth, Schmitt-Egenolf,Marcus, Kaye,James A, Gembert,Karin, Rothman,Kenneth J, Kieler,Helle, Dedman,Daniel, Houben,Eline, Gutiérrez,Lia, Hallas,Jesper, and Perez-Gutthann,Susana

Abstract

Alejandro Arana,1 Anton Pottegård,2 Josephina G Kuiper,3 Helen Booth,4 Johan Reutfors,5 Brian Calingaert,6 Lars Christian Lund,2 Elizabeth Crellin,4 Marcus Schmitt-Egenolf,5,7 James A Kaye,8 Karin Gembert,5 Kenneth J Rothman,8 Helle Kieler,5 Daniel Dedman,4 Eline Houben,3 Lia Gutiérrez,1 Jesper Hallas,2 Susana Perez-Gutthann1 1Department of Epidemiology, RTI Health Solutions, Barcelona, 08028, Spain; 2Clinical Pharmacology, Pharmacy and Environmental Medicine, Institute of Public Health, University of Southern Denmark, Odense C, 5000, Denmark; 3The PHARMO Institute, Utrecht, 3528 AE, the Netherlands; 4Clinical Practice Research Datalink (CPRD), The Medicines and Healthcare Products Regulatory Agency, London, E14 4PU, UK; 5Centre for Pharmacoepidemiology, Karolinska Institutet, Solna, 171 76, Stockholm, Sweden; 6Department of Epidemiology, RTI Health Solutions, Research Triangle Park, NC, 27709-2194, USA; 7Department of Public Health and Clinical Medicine, Umeå University, Umeå, 901 87, Sweden; 8Department of Epidemiology, RTI Health Solutions, Waltham, MA, 02451-1623, USACorrespondence: Alejandro AranaDepartment of Epidemiology, RTI Health Solutions, Av. Diagonal 605, 9-1, Barcelona, 08028, SpainTel +34 93 362 2805Fax +34 93 414 2610Email aarana@rti.orgPurpose: Evidence is insufficient to infer whether topical calcineurin inhibitors (TCIs; tacrolimus and pimecrolimus) cause malignancy. The study objective was to estimate the long-term risk of skin cancer and lymphoma associated with topical TCI use in adults and children, separately.Patients and Methods: A cohort study in Denmark, Sweden, UK, and the Netherlands was conducted. Adjusted incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated for nonmelanoma skin cancer (NMSC), melanoma, cutaneous T-cell lymphoma (CTCL), non-Hodgkin lymphoma (NHL) excluding CTCL, and Hodgkin lymphoma (HL) in new users of TCIs versus users of moderate/high-potency topical corticosteroids.Results: The study i

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results